UK Picks Rolls-Royce for Next-Generation Atomic Power Technology
The UK chose Rolls-Royce Plc to provide technology for the country's first small modular reactor, or SMR, according to a statement published Tuesday.
It's the culmination of a competition launched almost two years ago to select a company to design what's billed as a cheaper and easier way to build nuclear power plants.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $42.94, denoting a +2.02% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of 0.55%. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Shares of the company have appreciated by 11.97% over the course of the past month, outperforming the Medical sector's gain of 3.49% and the S&P 500's gain of 6.29%. Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.54 per share, which would represent a year-over-year decline of 3.36%. At the same time, our most recent consensus estimate is projecting a revenue of $5.89 million, reflecting a 1032.88% rise from the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.54 per share and revenue of $39.95 million, indicating changes of -27.65% and +7.06%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 1.68% fall in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 76, placing it within the top 31% of over 250 industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Another Milestone: Arctech Ranks World's No. 2 in Solar Tracker Market
KUNSHAN, China, June 10, 2025 /PRNewswire/ -- Recently, Wood Mackenzie, a world-renowned energy research firm, released its 2025 Global Solar PV Tracker Market Share Report. Arctech surged to the second position globally with a 16% market share, while also claiming the top spot in key markets such as India, the Middle East, and Asia-Pacific, demonstrating strong global competitiveness. 01 Industry-Leading Growth With an astonishing 113% year-on-year growth rate, Arctech became the only top-10 manufacturer to exceed 100% y-o-y growth, far exceeding the industry average. 02 Dominance Across Multiple Regional Markets Notably, Arctech has established leadership in several key markets: Middle East: Topped the market again, becoming the region's most preferred tracker supplier. India & Asia-Pacific: Maintained the No.1 position for two consecutive years, further solidifying market dominance. Europe, Saudi Arabia & Emerging Markets: Steadily growing market share, reflecting the success of our global expansion strategy. In 2024, Arctech's global tracker shipments reached 17.41 GW, supported by a robust production-sales-service network spanning three continents—including 4 service centers、six producing bases and 17 branches—delivering end-to-end services from design to O&M for global customers. 03 "Tracker+" Strategy Opens a New Chapter in Globalization With new producing bases in Saudi Arabia and Brazil, along with a European logistics hub, Arctech has built a globally integrated supply chain. Its differentiated competitive edge has secured multiple GW-level projects in India, the UAE, Argentina, and beyond, validating its innovative R&D and localized operations. SNEC 2025: A Grand Showcase Ahead From June 11th–13th, Arctech will unveil its full suite of "Tracker+" and "Green Power+" solutions at SNEC (Booth: 3H-A110), showcasing smart energy solutions for complex scenarios and driving the global energy transition forward. View original content to download multimedia: SOURCE Arctech Solar Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Geek Vibes Nation
an hour ago
- Geek Vibes Nation
How ChatGPT Bots Handle Client DMs While I Sleep – And Land Me New Deals
A good fit Ready to start Needing more info' This prompt works with DM automation tools that support branching logic. I collect info while I sleep – and wake up knowing which leads are warm. Claude Prompt #6 – Turn Chat Transcripts Into CRM Notes Prompt: 'Summarize this DM chat into 3 bullet points for my CRM: Who they are What they need How to follow up' This is huge when you're juggling 20 conversations. Claude acts like a personal assistant that cleans up your notes, flags key info, and saves it to Notion, Airtable, or whatever you use. AI DM Bot Comparison Use Case Best Model Why It Works Warm intro DM ChatGPT Fast, friendly, low-friction copy Deep context follow-up Claude Reads nuance and builds trust FAQ automation ChatGPT Clear, reusable, scalable replies Lead qualification Claude Detects readiness, helps filter CRM note generation Claude Great for summarizing long convos The Real Win – Focus on Closing, Not Replying Since I implemented this ChatGPT + Claude + Chatronix setup, I spend less time chasing leads and more time closing deals. I don't lose prospects because I replied too late. I don't drop the ball on follow-ups. And I don't miss qualified leads buried in my DMs. It's not about automating relationships – it's about automating friction so real connection can happen. Want your DMs to work while you rest? ✅ Visit Chatronix and set up your dream AI sales assistant – without hiring anyone. Emily Henry writes for UKWritings Reviews and Write My Research Paper . She writes articles on many subjects including writing great resumes. Emily is also an editor at State Of Writing .
